On August 24, Novartis announced that the CD19 CAR-T therapy Kymriah second-line treatment of aggressive B-cell non-Hodgkin lymphoma (B-NHL) Phase III clinical BELINDA did not meet the primary endpoint EFS. This means that the phase 3 clinical study of BELINDA has failed, and Kymriah's plan to expand the indications to achieve greater volume has failed.

It is worth mentioning that Novartis has long regarded the expansion of Kymriah indications as the key to achieving its CAR-T ambitions. The failure of the second-line B-NHL clinical failure study undoubtedly weakened its expansion in CAR-T. Competitive strength in the field of disease treatment.